Next Article in Journal
Green Synthesis and Application of Platinum-Based Catalysts for Fuel Cells
Previous Article in Journal
Pomolic Acid from the Dong Botanical Drug Madeng’ai Suppresses TNF-α-Induced Inflammatory Response in RA-HFLS by Inhibiting NF-κB Signaling Pathway Activation
Previous Article in Special Issue
Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 31
Issue 10
10.3390/molecules31101561
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Correction to Molecules 2023, 28(16), 6035.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Li et al. Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation. Molecules 2023, 28, 6035

by
Wenqi Li
1,
Shuwen Zhu
1,
Jing Liu
1,
Zhigang Liu
1,
Honggang Zhou
1,2,
Qianyi Zhang
1,
Yue Yang
1,
Li Chen
1,
Xiaowei Guo
1,
Tiantian Zhang
1,
Lingxin Meng
1,
Dan Chai
1,
Guodong Tang
3,*,
Xiaohe Li
1,* and
Cheng Yang
1,2,*
1
State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, China
2
Tianjin International Joint Academy of Biomedicine, Tianjin 300457, China
3
Department of Cardiology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
*
Authors to whom correspondence should be addressed.
Molecules 2026, 31(10), 1561; https://doi.org/10.3390/molecules31101561
Submission received: 17 April 2026 / Accepted: 24 April 2026 / Published: 8 May 2026
(This article belongs to the Special Issue Recent Advances in Cardiovascular Drug Discovery and Development)
Browse Figure
Versions Notes
In the original publication [1], there was a mistake in Figure 1. The authors noticed an error in Figure 1b when they reviewed this published work. The incorrect image was used for the ISO + Met group. The corrected Figure 1 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Li, W.; Zhu, S.; Liu, J.; Liu, Z.; Zhou, H.; Zhang, Q.; Yang, Y.; Chen, L.; Guo, X.; Zhang, T.; et al. Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation. Molecules 2023, 28, 6035. [Google Scholar] [CrossRef] [PubMed]
Molecules 31 01561 g001
Figure 1. ZB prevents ISO-induced cardiac dysfunction. (a) Dosing regimen in ISO-induced cardiac fibrosis model. Mice were treated by daily subcutaneous injection of 10 mg kg−1 d−1 ISO for 7 days. For 7 days, 10 mg/kg, 20 mg/kg ZB, 30 mg/kg Met or equal volumes of Saline was gavaged daily as indicated. Met was used as a positive control; (b) Representative echocardiographic M-mode images of left ventricles from mice at day 8; (c) Echocardiographic measurement of LVEF (n = 6); (d) Echocardiographic measurement of LVFS (n = 6); (e) Quantitative analysis of LVPW;d (n = 6); (f) The mRNA levels of ANP in heart tissues (n = 6); (g) The mRNA levels of BNP in heart tissues (n = 6); Quantification of ANP and BNP were normalized to GAPDH. The data are shown as mean ± SEM (one-way ANOVA with Tukey’s post-hoc multiple comparison tests). ***, p < 0.001, ****, p < 0.0001 vs. Saline; #, p < 0.05, ##, p < 0.01, ###, p < 0.001, ####, p < 0.0001 vs. ISO. ISO, isoproterenol; Met, metoprolol; ZB, Zanubrutinib; LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening; LVPW;d, diastolic left ventricular posterior wall thickness.
Figure 1. ZB prevents ISO-induced cardiac dysfunction. (a) Dosing regimen in ISO-induced cardiac fibrosis model. Mice were treated by daily subcutaneous injection of 10 mg kg−1 d−1 ISO for 7 days. For 7 days, 10 mg/kg, 20 mg/kg ZB, 30 mg/kg Met or equal volumes of Saline was gavaged daily as indicated. Met was used as a positive control; (b) Representative echocardiographic M-mode images of left ventricles from mice at day 8; (c) Echocardiographic measurement of LVEF (n = 6); (d) Echocardiographic measurement of LVFS (n = 6); (e) Quantitative analysis of LVPW;d (n = 6); (f) The mRNA levels of ANP in heart tissues (n = 6); (g) The mRNA levels of BNP in heart tissues (n = 6); Quantification of ANP and BNP were normalized to GAPDH. The data are shown as mean ± SEM (one-way ANOVA with Tukey’s post-hoc multiple comparison tests). ***, p < 0.001, ****, p < 0.0001 vs. Saline; #, p < 0.05, ##, p < 0.01, ###, p < 0.001, ####, p < 0.0001 vs. ISO. ISO, isoproterenol; Met, metoprolol; ZB, Zanubrutinib; LVEF, left ventricular ejection fraction; LVFS, left ventricular fractional shortening; LVPW;d, diastolic left ventricular posterior wall thickness.
Molecules 31 01561 g001
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Li, W.; Zhu, S.; Liu, J.; Liu, Z.; Zhou, H.; Zhang, Q.; Yang, Y.; Chen, L.; Guo, X.; Zhang, T.; et al. Correction: Li et al. Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation. Molecules 2023, 28, 6035. Molecules 2026, 31, 1561. https://doi.org/10.3390/molecules31101561

AMA Style

Li W, Zhu S, Liu J, Liu Z, Zhou H, Zhang Q, Yang Y, Chen L, Guo X, Zhang T, et al. Correction: Li et al. Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation. Molecules 2023, 28, 6035. Molecules. 2026; 31(10):1561. https://doi.org/10.3390/molecules31101561

Chicago/Turabian Style

Li, Wenqi, Shuwen Zhu, Jing Liu, Zhigang Liu, Honggang Zhou, Qianyi Zhang, Yue Yang, Li Chen, Xiaowei Guo, Tiantian Zhang, and et al. 2026. "Correction: Li et al. Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation. Molecules 2023, 28, 6035" Molecules 31, no. 10: 1561. https://doi.org/10.3390/molecules31101561

APA Style

Li, W., Zhu, S., Liu, J., Liu, Z., Zhou, H., Zhang, Q., Yang, Y., Chen, L., Guo, X., Zhang, T., Meng, L., Chai, D., Tang, G., Li, X., & Yang, C. (2026). Correction: Li et al. Zanubrutinib Ameliorates Cardiac Fibrosis and Inflammation Induced by Chronic Sympathetic Activation. Molecules 2023, 28, 6035. Molecules, 31(10), 1561. https://doi.org/10.3390/molecules31101561

Article Metrics

Back to TopTop